The authors investigated PK/PD and safety in the administration of benralizumab to children. The number of patients was limited to approximately 30, yet the findings were not significantly different from those of adults. I have identified specific points requiring your attention.

1. Reason for Including Patients of Different Age Groups from Japan in PK Study: Kindly provide a brief explanation for the inclusion of patients from two different age groups in the PK study conducted in Japan.
2. Discussion on Dosage Adjustment According to Age and Weight: How the dosage of benralizumab would be determined in real-world clinical practice based on the obtained results?
3. Graphical Representation of Peripheral Blood Eosinophil Counts in ADA Cases: Include a graph illustrating the time course of peripheral blood eosinophil counts for the four cases with ADA. The graph should indicate when ADA was detected. A Supplemental Figure would be acceptable.